Loading organizations...
§ Private Profile · San Jose, CA, USA
Clinical-stage biotech develops ultra-sustained analgesics for post-surgical pain management, reducing opioid reliance.
Allay Therapeutics has raised $118.0M across 2 funding rounds.
Key people at Allay Therapeutics.
Allay Therapeutics has raised $118.0M in total across 2 funding rounds.
Allay Therapeutics is a clinical-stage biotechnology company developing ultra-sustained analgesic products for post-surgical pain management, based in Menlo Park, California, with additional operations in Singapore. The organization utilizes proprietary polymer technology to deliver non-opioid pain medication locally to surgical sites over several weeks, aiming to reduce patient reliance on opioids following orthopedic procedures. Operating with approximately 40 employees, the company generates around $10 million in annual revenue through strategic licensing agreements. Allay Therapeutics has raised over $100 million in total venture capital funding from prominent investors including New Enterprise Associates, Lightstone Ventures, and Temasek-backed ClavystBio. The firm also maintains international distribution partnerships with pharmaceutical manufacturers such as Maruishi Pharmaceutical for markets in Japan, South Korea, and Taiwan. The enterprise was founded in 2017 through incubation by medical device incubator The Foundry and Lightstone Ventures.
Allay Therapeutics has raised $118.0M in total across 2 funding rounds.
Allay Therapeutics's investors include Lightstone Ventures, Anselm Tan, Arboretum Ventures, New Enterprise Associates (NEA), Tak Cheung, New Enterprise Associates, Brandon Capital, EDBI, IPD Capital, Maruishi Pharmaceutical, NEA, SGInnovate.
Allay Therapeutics has raised $118.0M across 2 funding rounds. Most recently, it raised $58.0M Series D in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $58M Series D | Lightstone Ventures, Anselm TAN | Arboretum Ventures, NEW Enterprise Associates (NEA), TAK Cheung, NEW Enterprise Associates, Brandon Capital, EDBI, IPD Capital, Maruishi Pharmaceutical, NEA, Sginnovate, Vertex Growth, Vertex Ventures HC | Announced |
| Sep 1, 2021 | $60M Series C | Arboretum Ventures | Lightstone Ventures, NEW Enterprise Associates (NEA), TAK Cheung, NEW Enterprise Associates, Brandon Capital, NEA, Pavilion Capital, Temasek, Vertex Growth, Vertex Ventures HC, WTT Investment | Announced |
Key people at Allay Therapeutics.
Allay Therapeutics is a clinical-stage biotechnology company developing ultra-sustained, non-opioid analgesic products to transform post-surgical pain management and patient recuperation.[1][2][3] Its proprietary platform combines validated local analgesics with biopolymers to create dissolvable implants that deliver targeted pain relief at the surgical site for weeks, an order of magnitude longer than current longest-lasting treatments, serving patients, surgeons, and healthcare systems burdened by opioid-related addiction, prolonged recovery, and high costs.[2][3][4] The company operates from the San Francisco Bay Area and Singapore, with recent milestones including FDA acceptance of its Investigational New Drug (IND) application for lead candidate ATX101 in October 2024 and a $57.5M Series D financing round to advance its pipeline.[3][8]
Allay Therapeutics emerged from The Foundry incubator and Lightstone Venture’s Singapore Fund, uniting a global team of entrepreneurs, scientists, clinicians, and innovators across San Francisco and Singapore to address stalled innovation in pain management.[2][3][5] While specific founding year and individual founders are not detailed in available sources, the company's platform was shaped by these incubators, focusing on non-opioid solutions amid the opioid crisis.[2][3] Early traction includes expansion of its clinical and scientific advisory boards in October 2024, FDA IND clearance for ATX101, and securing Series D funding from investors like Vertex Ventures HC and ClavystBio, signaling strong validation of its vision.[3][5][8]
Allay rides the wave of non-opioid innovation amid the global push to combat the opioid epidemic, which drives addiction, extended hospitalizations, and healthcare costs in post-surgical care.[1][3] Timing aligns with regulatory tailwinds like FDA fast-tracking non-addictive analgesics and Singapore's R&D ecosystem accelerating life sciences via investors like ClavystBio and Lightstone Ventures.[3][8] Market forces favoring Allay include surging demand for localized, long-acting therapies—evidenced by its Series D raise—and biotech trends in biopolymer drug delivery, positioning it to influence ecosystem shifts toward safer recovery tools and reduced systemic drug reliance.[2][4][8]
Allay is poised to advance ATX101 into clinical trials following FDA IND clearance, with its $57.5M Series D fueling pipeline expansion and global scaling from Singapore to worldwide markets.[3][8] Trends like AI-accelerated drug development (via advisors) and biopolymer advancements will shape its path, potentially disrupting a market dominated by short-acting or addictive options.[1][5] Its influence may grow by setting new standards for post-surgical care, enabling faster patient mobility and lower system costs, ultimately fulfilling its mission to end the era of inadequate pain management.[1][4]
